TMC Life Sciences reports 27% surge in profit before taxes in FY 2023

The total profit increased to RM40.9m compared to the previous fiscal year.

Increased capacity at Thomson Hospital Kota Damansara (THKD) and the recovery of the fertility business helped TMC Life Sciences earnings to grow.

Aside from its total profit, its revenue grew 28% to RM311.4m in the current fiscal year.   

“Specifically, the hospital and fertility business segments contributed RM272.3m (2022: RM208.8m) and RM37.3m (2022: RM32.0m) in revenue, respectively, for the period ending June 30, 2023,” read the statement.

Key factors boosting TMC Life Science’s earnings and revenue include the “recruitment of healthcare professionals, expanded bed capacity, diversification of services, handling higher case intensity, and an ongoing marketing effort to bolster local and international branding.” 

The group is seen to capitalise on increased capacity at THKD, the resurgence of the fertility business, and medical tourism with an eye on growth prospects and opportunities in the region.